First Trust Advisors’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$28.2M Buy
352,315
+182,047
+107% +$15M 0.02% 786
2025
Q4
$14.5M Buy
170,268
+42,974
+34% +$3.53M 0.01% 966
2025
Q3
$9.9M Sell
127,294
-33,056
-21% -$2.58M 0.01% 1096
2025
Q2
$12.5M Sell
160,350
-8,739
-5% -$652K 0.01% 1020
2025
Q1
$12.3M Sell
169,089
-101,522
-38% -$7.27M 0.01% 991
2024
Q4
$20M Buy
270,611
+108,057
+66% +$7.56M 0.02% 862
2024
Q3
$10.7M Sell
162,554
-127,426
-44% -$9.26M 0.01% 1022
2024
Q2
$26.8M Buy
289,980
+271,632
+1,480% +$24.1M 0.03% 682
2024
Q1
$1.75M Buy
18,348
+5,614
+44% +$472K ﹤0.01% 1792
2023
Q4
$971K Sell
12,734
-84,089
-87% -$5.85M ﹤0.01% 1974
2023
Q3
$6.71M Buy
96,823
+90,927
+1,542% +$7.31M 0.01% 1110
2023
Q2
$556K Buy
5,896
+528
+10% +$45.9K ﹤0.01% 2113
2023
Q1
$444K Sell
5,368
-15,584
-74% -$1.22M ﹤0.01% 2164
2022
Q4
$1.56M Sell
20,952
-98,710
-82% -$7.61M ﹤0.01% 1806
2022
Q3
$9.89M Sell
119,662
-143,648
-55% -$13.8M 0.01% 950
2022
Q2
$25M Buy
263,310
+8,741
+3% +$905K 0.03% 625
2022
Q1
$30M Sell
254,569
-39,312
-13% -$4.41M 0.03% 652
2021
Q4
$38.1M Buy
293,881
+141,180
+92% +$16.5M 0.04% 582
2021
Q3
$17.3M Sell
152,701
-1,656,824
-92% -$189M 0.02% 833
2021
Q2
$187M Buy
1,809,525
+1,686,487
+1,371% +$159M 0.2% 127
2021
Q1
$10.3M Sell
123,038
-46,466
-27% -$3.93M 0.01% 927
2020
Q4
$15.5M Buy
169,504
+49,976
+42% +$4.15M 0.02% 697
2020
Q3
$9.54M Sell
119,528
-1,400,820
-92% -$109M 0.02% 755
2020
Q2
$105M Buy
1,520,348
+991,328
+187% +$70.5M 0.18% 132
2020
Q1
$33.3M Buy
529,020
+24,780
+5% +$1.79M 0.08% 404
2019
Q4
$39.2M Buy
504,240
+362,514
+256% +$28.3M 0.07% 442
2019
Q3
$10.4M Sell
141,726
-343,539
-71% -$24.1M 0.02% 804
2019
Q2
$29.9M Sell
485,265
-237,321
-33% -$14.4M 0.06% 445
2019
Q1
$46.1M Sell
722,586
-34,083
-5% -$1.95M 0.09% 281
2018
Q4
$38.6M Buy
756,669
+339,165
+81% +$17.2M 0.09% 276
2018
Q3
$24.2M Sell
417,504
-677,148
-62% -$33.1M 0.05% 533
2018
Q2
$53.1M Buy
1,094,652
+945,432
+634% +$44.1M 0.11% 199
2018
Q1
$6.94M Sell
149,220
-7,974
-5% -$346K 0.02% 893
2017
Q4
$5.91M Sell
157,194
-466,944
-75% -$17.1M 0.01% 963
2017
Q3
$22.7M Buy
+624,138
New +$23.8M 0.06% 445
2017
Q2
Sell
-202,209
Closed -$6.34M 2394
2017
Q1
$6.34M Sell
202,209
-614,751
-75% -$19.2M 0.02% 948
2016
Q4
$25.5M Sell
816,960
-305,475
-27% -$9.9M 0.08% 348
2016
Q3
$45.1M Sell
1,122,435
-76,644
-6% -$2.89M 0.13% 151
2016
Q2
$39.9M Sell
1,199,079
-90,864
-7% -$3.11M 0.13% 171
2016
Q1
$37.9M Sell
1,289,943
-1,721,025
-57% -$47.5M 0.12% 193
2015
Q4
$79.3M Buy
3,010,968
+890,622
+42% +$23.1M 0.21% 110
2015
Q3
$50.2M Sell
2,120,346
-1,542,324
-42% -$37.2M 0.15% 146
2015
Q2
$86.9M Sell
3,662,670
-396,654
-10% -$8.95M 0.23% 93
2015
Q1
$96.4M Buy
4,059,324
+907,692
+29% +$20.4M 0.28% 69
2014
Q4
$66.9M Sell
3,151,632
-286,884
-8% -$5.76M 0.23% 88
2014
Q3
$58.5M Buy
3,438,516
+2,528,616
+278% +$39.9M 0.23% 83
2014
Q2
$13M Buy
909,900
+512,922
+129% +$6.95M 0.05% 539
2014
Q1
$4.91M Buy
+396,978
New +$4.58M 0.02% 975

Other funds holding EW

First Trust Advisors's EW Position: Q1 2026 in Review

First Trust Advisors increased its Edwards Lifesciences (EW) stake by 107% in Q1 2026, buying an estimated $15M and bringing the position to 352,315 shares worth $28.2M. The position accounts for 0.02% of the portfolio, ranked #786.

First Trust Advisors first reported a position in EW in Q1 2014 and has held it in 48 quarters since. The position peaked at $187M in Q2 2021. 1,284 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • First Trust Advisors held 352,315 shares of Edwards Lifesciences worth $28.2M as of Q1 2026.
  • First Trust Advisors bought 182,047 Edwards Lifesciences shares in Q1 2026, an estimated $15M.
  • Edwards Lifesciences made up 0.02% of First Trust Advisors's portfolio in Q1 2026, its #786 holding.
  • First Trust Advisors first reported a position in Edwards Lifesciences in Q1 2014 and has held it in 48 quarters since.
  • First Trust Advisors's Edwards Lifesciences position peaked at $187M in Q2 2021.
  • 1,284 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on First Trust Advisors's 13F filing for Q1 2026, filed 13 May 2026.